Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup

Heinz Ludwig; Meletios A. Dimopoulos; Philippe Moreau; Wee Joo Chng; Hartmut Goldschmidt; Roman Hájek; Thierry Facon; Ludek Pour; Ruben Niesvizky; Albert Oriol; Laura Rosiñol; Aleksandr Suvorov; Gianluca Gaidano; Tomas Pika; Katja Weisel; Vesselina Goranova-Marinova; Antonio Palumbo; Heidi H. Gillenwater; Nehal Mohamed; Sanjay Aggarwal; Shibao Feng; Douglas Joshua

doi:10.1080/10428194.2017.1298755

Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup

Heinz Ludwig
, Meletios A. Dimopoulos
, Philippe Moreau
, Wee Joo Chng
, Hartmut Goldschmidt
, Roman Hájek
, Thierry Facon
, Ludek Pour
, Ruben Niesvizky
, Albert Oriol
, Laura Rosiñol
, Aleksandr Suvorov
, Gianluca Gaidano
, Tomas Pika
, Katja Weisel
, Vesselina Goranova-Marinova
, Antonio Palumbo
, Heidi H. Gillenwater
, Nehal Mohamed
, Sanjay Aggarwal

Shibao Feng, Douglas Joshua

Department of Translational Medicine

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	2501-2504
Number of pages	4
Journal	Leukemia and Lymphoma
Volume	58
Issue number	10
DOIs	https://doi.org/10.1080/10428194.2017.1298755
Publication status	Published - 3 Oct 2017

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1080/10428194.2017.1298755

Cite this

Ludwig, H., Dimopoulos, M. A., Moreau, P., Chng, W. J., Goldschmidt, H., Hájek, R., Facon, T., Pour, L., Niesvizky, R., Oriol, A., Rosiñol, L., Suvorov, A., Gaidano, G., Pika, T., Weisel, K., Goranova-Marinova, V., Palumbo, A., Gillenwater, H. H., Mohamed, N., ... Joshua, D. (2017). Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup. Leukemia and Lymphoma, 58(10), 2501-2504. https://doi.org/10.1080/10428194.2017.1298755

@article{1deb7336bfb84c87ab88bb1a9cfc10c1,

title = "Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup",

author = "Heinz Ludwig and Dimopoulos, \{Meletios A.\} and Philippe Moreau and Chng, \{Wee Joo\} and Hartmut Goldschmidt and Roman H{\'a}jek and Thierry Facon and Ludek Pour and Ruben Niesvizky and Albert Oriol and Laura Rosi{\~n}ol and Aleksandr Suvorov and Gianluca Gaidano and Tomas Pika and Katja Weisel and Vesselina Goranova-Marinova and Antonio Palumbo and Gillenwater, \{Heidi H.\} and Nehal Mohamed and Sanjay Aggarwal and Shibao Feng and Douglas Joshua",

note = "Funding Information: The ENDEAVOR study was supported by Onyx Pharmaceuticals, Inc., an Amgen subsidiary. The authors would like to thank Jesse Potash of Amgen Inc. for medical writing assistance.",

year = "2017",

month = oct,

day = "3",

doi = "10.1080/10428194.2017.1298755",

language = "English",

volume = "58",

pages = "2501--2504",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Taylor and Francis Ltd.",

number = "10",

}

Ludwig, H, Dimopoulos, MA, Moreau, P, Chng, WJ, Goldschmidt, H, Hájek, R, Facon, T, Pour, L, Niesvizky, R, Oriol, A, Rosiñol, L, Suvorov, A, Gaidano, G, Pika, T, Weisel, K, Goranova-Marinova, V, Palumbo, A, Gillenwater, HH, Mohamed, N, Aggarwal, S, Feng, S & Joshua, D 2017, 'Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup', Leukemia and Lymphoma, vol. 58, no. 10, pp. 2501-2504. https://doi.org/10.1080/10428194.2017.1298755

Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup. / Ludwig, Heinz; Dimopoulos, Meletios A.; Moreau, Philippe et al.
In: Leukemia and Lymphoma, Vol. 58, No. 10, 03.10.2017, p. 2501-2504.

Research output: Contribution to journal › Letter › peer-review

TY - JOUR

T1 - Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma

T2 - results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup

AU - Ludwig, Heinz

AU - Dimopoulos, Meletios A.

AU - Moreau, Philippe

AU - Chng, Wee Joo

AU - Goldschmidt, Hartmut

AU - Hájek, Roman

AU - Facon, Thierry

AU - Pour, Ludek

AU - Niesvizky, Ruben

AU - Oriol, Albert

AU - Rosiñol, Laura

AU - Suvorov, Aleksandr

AU - Gaidano, Gianluca

AU - Pika, Tomas

AU - Weisel, Katja

AU - Goranova-Marinova, Vesselina

AU - Palumbo, Antonio

AU - Gillenwater, Heidi H.

AU - Mohamed, Nehal

AU - Aggarwal, Sanjay

AU - Feng, Shibao

AU - Joshua, Douglas

N1 - Funding Information: The ENDEAVOR study was supported by Onyx Pharmaceuticals, Inc., an Amgen subsidiary. The authors would like to thank Jesse Potash of Amgen Inc. for medical writing assistance.

PY - 2017/10/3

Y1 - 2017/10/3

UR - https://www.scopus.com/pages/publications/85015635745

U2 - 10.1080/10428194.2017.1298755

DO - 10.1080/10428194.2017.1298755

M3 - Letter

SN - 1042-8194

VL - 58

SP - 2501

EP - 2504

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 10

ER -

Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup

UN SDGs

Access to Document

Other files and links

Cite this